Yea Christopher (CIK 1691102) reported 34 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-11). Recent activity: Sell KALV (229,918 shares), Buy KALV (33,800 shares), Sell KALV (33,800 shares), Buy KALV (3,125 shares), Sell KALV (1,966 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 229,918 | $0 |
| 2026-05-29 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 33,800 | $238,966 |
| 2026-05-29 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 33,800 | $905,225 |
| 2026-05-27 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,125 | $0 |
| 2026-05-27 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 1,966 | $52,645 |
| 2026-05-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,750 | $0 |
| 2026-05-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 2,358 | $63,158 |
| 2026-05-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 1,774 | $0 |
| 2026-05-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 1,108 | $29,650 |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,750 | $0 |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,125 | $0 |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 4,347 | $67,683 |
| 2026-02-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 1,109 | $16,635 |
| 2026-02-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 1,774 | $0 |
| 2025-11-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,750 | $0 |
| 2025-11-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,125 | $0 |
| 2025-11-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 4,331 | $58,252 |
| 2025-11-21 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 87,390 | $0 |
| 2025-11-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 4,205 | $0 |
| 2025-11-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 2,683 | $38,850 |
| 2025-08-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,125 | $0 |
| 2025-08-26 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 1,954 | $26,223 |
| 2025-08-25 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 3,750 | $0 |
| 2025-08-25 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Sell | 2,362 | $31,226 |
| 2025-08-19 | KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | Buy | 4,203 | $0 |
Source: SEC Form 4 filings · as of 2026-06-11